Production (Stage)
Bone Biologics Corporation
BBLG
$4.98
$0.040.81%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -21.96% | -17.12% | 0.54% | 2.34% | 31.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.39% | -55.25% | -59.98% | -43.02% | 17.33% |
| Operating Income | 39.39% | 55.25% | 59.98% | 43.02% | -17.33% |
| Income Before Tax | 30.16% | 54.04% | 36.35% | 11.81% | -35.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.16% | 54.04% | 36.35% | 11.81% | -35.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.16% | 54.04% | 36.35% | 11.81% | -35.51% |
| EBIT | 39.39% | 55.25% | 59.98% | 43.02% | -17.33% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 73.16% | 92.77% | 84.75% | 77.60% | 63.52% |
| Normalized Basic EPS | 84.60% | 95.38% | 90.15% | 79.57% | 65.74% |
| EPS Diluted | 73.16% | 92.77% | 84.75% | 77.60% | 63.52% |
| Normalized Diluted EPS | 84.60% | 95.38% | 90.15% | 79.57% | 65.74% |
| Average Basic Shares Outstanding | 363.78% | 382.17% | 370.24% | 472.69% | 1,342.06% |
| Average Diluted Shares Outstanding | 363.78% | 382.17% | 370.24% | 472.69% | 1,342.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |